Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so

The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdi

Investors need to pay close attention to ATRC stock based on the movements in the options market lat

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a

https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffl

U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price targ

Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and rai

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on

BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price targ

AtriCure is building a broader surgical platform across appendage management, ablation, and postoper

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial

On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduc

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on Aug

On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76.

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high

UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price targe

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the q

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Est

AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the

AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from th

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consens

AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analy

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The la

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises

2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consens

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price ta

Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and low

AtriCure (NASDAQ:ATRC) is looking for FY2026 Adj EPS of $0.09-$0.15 vs $(0.04) analyst estimate. Aff

AtriCure (NASDAQ:ATRC) affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.0

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.06 per share which beat the analyst consens